The project investigates certain cancer of the soft tissue or bone (soft tissue and bone sarcomas) that have a mutation in the retinoblastoma tumour suppressor protein (RB1). Mutations in RB1 are found in nearly 30% of the childhood forms of these cancers. Although soft tissue or bone sarcomas are overall rare cancers, they represent the 2nd highest cause of cancer death in children and young adults. New, more effective treatments with fewer side effects are urgently needed for these young patients.
Exploring retinoblastoma protein loss as an actionable target in paediatric bone and soft tissue sarcoma
Professor Sibylle Mittnacht
UCL Cancer Institute
12 February 2018